Evidence map›Paper›PMID 36139092›Full record

ArticleBiomolecules2022

SARS-CoV-2 Invasion and Pathological Links to Prion Disease.

Walter J Lukiw, Vivian R Jaber, Aileen I Pogue, Yuhai Zhao

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. 1-L Transcription in Prion Diseases.International journal of molecular sciences · 2024
    Article
  4. Article
  5. Prion Disease After COVID-19: A Case Report.The American journal of case reports · 2023
    Article
  6. Long COVID as a Tauopathy: Of "Brain Fog" and "Fusogen Storms".International journal of molecular sciences · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Walter J LukiwLSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.
Vivian R JaberLSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.
Aileen I PogueAlchem Biotek Research, Toronto, ON M5S 1A8, Canada.
Yuhai ZhaoLSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.
Louisiana State University Health Sciences Center New Orleans · US

Funding

microRNA (miRNA) signaling in Alzheimer's disease(AD)R01AG038834 · NIA · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G. · 2011 to 2020
$3.3M
Gene Expression in Alzheimer's DiseaseR01AG018031 · NIA · LSU HEALTH SCIENCES CENTER · PI LUKIW, WALTER J · 2001 to 2006
$1.4M
NIA NIH HHS R01 AG018031NIA NIH HHS R01 AG038834NIH HHS AG038834NIH HHS AG18031
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 disease, is a highly infectious and transmissible viral pathogen that continues to impact human health globally. Nearly ~600 million people have been infected with SARS-CoV-2, and about half exhibit some degree of continuing health complication, generically referred to as long COVID. Lingering and often serious neurological problems for patients in the post-COVID-19 recovery period include brain fog, behavioral changes, confusion, delirium, deficits in intellect, cognition and memory issues, loss of balance and coordination, problems with vision, visual processing and hallucinations, encephalopathy, encephalitis, neurovascular or cerebrovascular insufficiency, and/or impaired consciousness. Depending upon the patient’s age at the onset of COVID-19 and other factors, up to ~35% of all elderly COVID-19 patients develop a mild-to-severe encephalopathy due to complications arising from a SARS-CoV-2-induced cytokine storm and a surge in cytokine-mediated pro-inflammatory and immune signaling. In fact, this cytokine storm syndrome: (i) appears to predispose aged COVID-19 patients to the development of other neurological complications, especially those who have experienced a more serious grade of COVID-19 infection; (ii) lies along highly interactive and pathological pathways involving SARS-CoV-2 infection that promotes the parallel development and/or intensification of progressive and often lethal neurological conditions, and (iii) is strongly associated with the symptomology, onset, and development of human prion disease (PrD) and other insidious and incurable neurological syndromes. This commentary paper will evaluate some recent peer-reviewed studies in this intriguing area of human SARS-CoV-2-associated neuropathology and will assess how chronic, viral-mediated changes to the brain and CNS contribute to cognitive decline in PrD and other progressive, age-related neurodegenerative disorders.

Indexed as

COVID-19EncephalitisNervous System DiseasesPrion DiseasesAgedCytokine Release SyndromeCytokinesHumansPost-Acute COVID-19 SyndromeSARS-CoV-2Cytokinesangiotensin-converting enzyme 2 receptor (ACE2R)Creutzfeldt–Jakob disease (CJD)cytokine stormmicroRNA (miRNA)miRNA-146amiRNA-155prion disease (PrD)SARS-CoV-2

Identifiers

PMID36139092
PMCPMC9496025
OpenAlexW4295106556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.